Back to Authors

Li, April Yingfang

Mayo Clinic

Northeast Ohio Medical University

Citations 1

Immunosuppressive Therapy in Heart Transplantation
Li, April Yingfang, Nwankwo, Ifeyinwa S., Huang, Zhi , Lu, Yun , Yao, Yali, Li, Yan , Zhang, Bin

Advances in Medical Diagnosis, Treatment, and Care | January 25, 2017 | Volume: No volume available | Issue: No issue available | Pages: 212-231

10.4018/978-1-5225-2092-4.ch012 Get It

Heart transplantation is a surgical procedure performed on patients with end-stage heart failure or other irreversible heart disease, Heart transplant prolongs the life of severe heart disease patients. Most of the receipts could survive more than 2-3 years, five-year survival rate could reach 70-80% with immunosuppressive therapy, rejection still an important problem after transplantation. Currently, traditional calcineurin inhibitors, antimetabolite agents, and steroids, wildly used after transplantation, the new generation of immunosuppressive medicines have been developed, and cell-based immunotherapy, as mesenchymal stem cell, myeloid-derived suppressor cells, dendritic cells, pluripotent cells and Treg cells are promising to be used in cellular immunotherapy in organ transplantation.